Purpose

This study will evaluate intrapleural administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in combination with Celecoxib and Gemcitabine in patients with histologically confirmed Malignant Pleural Mesothelioma (MPM) who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen. Eligible patients will be randomized 1:1 to either: 1. Treatment group: rAd-IFN + Celecoxib followed by Gemcitabine 2. Control group: Celecoxib followed by Gemcitabine Patients randomized to the treatment group will receive rAd-IFN administered into the pleural space via an Intrapleural catheter (IPC) or similar intrapleural device on study Day 1. The primary objective of this study is to compare the overall survival (OS) associated with rAd IFN, when administered with celecoxib and gemcitabine, versus that associated with celecoxib and gemcitabine alone for the treatment of patients with MPM

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Aged 18 years or older at the time of consent;
  2. Able to give informed consent;
  3. Has a confirmed histological diagnosis of MPM with histological type epithelioid or biphasic (predominantly [>50%] epithelioid). Histological diagnosis of MPM will be confirmed centrally using specimens or slides from tumor specimens obtained at the time of initial presentation or a subsequent procedure. Central confirmation of diagnosis with immunohistochemistry will be performed, and independent central confirmation will be required for study entry;
  4. Measurable disease, per modified Response Evaluation Criteria in Solid Tumor [RECIST] for pleural mesothelioma;
  5. Has failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, which may have been chemotherapeutic and/or immunotherapeutic treatment regimens for MPM which included at least 1 anti-folate and platinum combination regimen. Patients who have undergone primary surgical resection and/or radiation therapy to the pulmonary site are eligible to participate. For clarity, surgical resection and/or radiation therapy to the pulmonary site are not exclusionary and are not considered a line of therapy;
  6. Has a pleural space accessible for pleural catheter insertion. Patients with a previously inserted pleural catheter may be enrolled, and the pre-existing catheter can be used for vector administration as long as it is functional and has no evidence of local infection;
  7. Life expectancy >12 weeks in the judgement of the Investigator;
  8. Eastern Cooperative Oncology Group (ECOG) status of 1 or 0;
  9. Female and male patients:
  10. Female patients must be either postmenopausal (no menstrual period for a minimum of 12 months) or surgically sterile upon entry into the study. Female patients of childbearing potential must have a negative pregnancy test upon entry into this study and agree to use a highly effective method of contraception from Screening until 1 month following administration of gemcitabine;
  11. Highly effective methods of contraception that result in a low failure rate (i.e., <1% per year) when used consistently and correctly include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or sexual abstinence;
  12. True abstinence, when in line with the preferred and usual lifestyle of the patient, is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of study participation and for 1 month post-gemcitabine administration. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, and post-ovulation method) and withdrawal are not acceptable methods of contraception; and
  13. Male patients must be either surgically sterile or agree to use a double-barrier contraception method from Screening until 1 month post-gemcitabine administration; and
  14. Adequate laboratory values at Screening:
  15. Hemoglobin 9 g/dL;
  16. White blood cell count 3500/µL;
  17. Absolute neutrophil count 1500/µL;
  18. Platelet count 100,000/µL;
  19. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) below the upper limit of normal (ULN). It is expected that patients receiving anticoagulation therapy will not have INR and aPTT results that fall within normal limits. It is not intended to exclude these patients and, therefore, medical discretion is permitted for patients who have clinically acceptable results in regards to their current concomitant anticoagulant therapy;
  20. Aspartate aminotransferase (AST) 3 × ULN;
  21. Alanine aminotransferase (ALT) 3 × ULN;
  22. Total bilirubin 2 × ULN;
  23. Estimated glomerular filtration rate 50 mL/min/1.73 m2; and
  24. Serum albumin 2.5 g/dL.

Exclusion Criteria

  1. Is "treatment-naïve" (i.e., has not received at least 1 anti-folate and platinum combination regimen);
  2. Has previously received 3 or more lines of systemic chemotherapeutic or immunotherapeutic treatment;
  3. Has previously received treatment with gemcitabine;
  4. Has stage IV extrathoracic metastatic disease;
  5. Inadequate pulmonary function of clinical significance as per Investigator review;
  6. Clinically significant pericardial effusion (i.e., as judged by the Investigator and/or requiring drainage) detected by computed tomography (CT) scan at Screening;
  7. Prior therapy(ies), if applicable, must be completed according to the criteria below prior to vector administration:
  8. Cytotoxic chemotherapy, at least 21 days from last dose;
  9. Non-cytotoxic chemotherapy (e.g., small molecule inhibitor), at least 14 days from last dose;
  10. Monoclonal antibody, at least 3 half-lives from last dose;
  11. Non-antibody immunotherapy (e.g., tumor vaccine), at least 42 days from last dose;
  12. Radiotherapy, at least 14 days from last local site radiotherapy;
  13. Hematopoietic growth factor, at least 14 days from last dose; or
  14. Study drug, 30 days or 5 half-lives, whichever is longer, from last dose;
  15. Patient previously treated with IFNs (e.g., for chronic active hepatitis);
  16. Suspected/known hypersensitivity to IFN-α2b;
  17. Known hypersensitivity to celecoxib or sulfonamides;
  18. Impaired cardiac function or clinically significant cardiac disease including the following:
  19. New York Heart Association class III or IV congestive heart failure;
  20. Myocardial infarction within the last 12 months; and
  21. Patients known to have impaired left ventricular ejection fraction per institutional standards and of clinical significance as per Investigator review;
  22. Women who are pregnant or breastfeeding;
  23. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, depression, or psychiatric illness/social situations within the last 12 months;
  24. Patients with active, known, or suspected auto-immune disease or a syndrome that requires systemic or immunosuppressive agents (oral prednisolone or equivalent at a dose of <10 mg per day is permitted); NOTE: patients with vitiligo, residual hypothyroidism due to auto immune disease only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll;
  25. History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs;
  26. History of ulcer disease or gastrointestinal bleeding;
  27. Uncontrolled or poorly controlled hypertension requiring 3 or more anti-hypertensive drugs;
  28. Patients receiving lithium;
  29. Any significant disease which, in the opinion of the Investigator, would place the patient at increased risk of harm if he/she participated in the study;
  30. History of malignancy of other organ system within the past 5 years, except treated basal cell or squamous cell carcinoma of the skin, or early stage prostate cancer (stage T2a or smaller, prostate specific antigen <10 ng/mL, Gleason score <6); or
  31. Has a congenital or acquired immunodeficiency, including patients with known history of infection with human immunodeficiency virus.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Treatment Group
rAd-IFN (Study Day 1) + celecoxib oral product (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 [i.e., Days 1 and 8 of the first gemcitabine treatment cycle], gemcitabine will be repeated every 3 weeks until disease progression/early termination [ET]
  • Biological: rAd-IFN
    Adenovirus-Delivered Interferon Alpha-2b
    Other names:
    • Nadofaragene firadenovec
  • Drug: Celecoxib Oral Product
    400 mg twice daily
    Other names:
    • COX II Inhibitor
  • Drug: Gemcitabine
    1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle and continued every 3 weeks until disease progression/ early termination
    Other names:
    • Chemotherapy
Placebo Comparator
Control Group
Celecoxib oral product (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 [i.e., Days 1 and 8 of the first gemcitabine treatment cycle], gemcitabine will be repeated every 3 weeks until disease progression/ET.
  • Drug: Celecoxib Oral Product
    400 mg twice daily
    Other names:
    • COX II Inhibitor
  • Drug: Gemcitabine
    1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle and continued every 3 weeks until disease progression/ early termination
    Other names:
    • Chemotherapy

Recruiting Locations

University of Maryland Medical Center
Baltimore, Maryland 21201
Contact:
Joseph Friedberg, Dr
410-328-6366
JFriedberg@som.umaryland.edu

More Details

NCT ID
NCT03710876
Status
Recruiting
Sponsor
Trizell Ltd

Study Contact

Aidan Doherty, M.Sc
+44 (0) 1844 355 625
aidan.doherty@trizell.com

Detailed Description

TITLE: A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma

PROTOCOL NUMBER: rAd-IFN-MM-301

STUDY DRUGS: Nadofaragene firadenovec (Recombinant adenovirus vector containing the human interferon alpha-2b gene: rAd-IFN), celecoxib, and gemcitabine

PHASE: 3

INDICATION: Malignant pleural mesothelioma (MPM)

SPONSOR: Trizell, Ltd.

SITES: Approximately 80 sites globally

OBJECTIVES:

The primary objective of this study is to compare the overall survival (OS) associated with rAd IFN, when administered with celecoxib and gemcitabine, versus that associated with celecoxib and gemcitabine alone for the treatment of patients with MPM who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen.

The secondary objectives of this study are:

- To compare between rAd-IFN, when administered with celecoxib and gemcitabine, versus that associated with celecoxib and gemcitabine alone for the treatment of patients with MPM who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen, with respect to:

- Survival rate at 12 months and every 6 months thereafter;

- Progression-free survival (PFS);

- Best response (complete response, partial response, or stable disease); and

- Safety of rAd-IFN; and

- To evaluate rAd-IFN, when administered with celecoxib and gemcitabine, in a sub-set of patients with MPM who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen, with respect to viral shedding and biodistribution.

The exploratory objectives of this study are:

• To compare between rAd-IFN, when administered with celecoxib and gemcitabine, versus that associated with celecoxib and gemcitabine alone for the treatment of patients with MPM who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen, with respect to:

- Health-related Quality-of-Life,

- The relationship between immunological status and response to treatment, and

- Biocorrelates of response to treatment.

POPULATION:

The population for this study is patients with histologically confirmed MPM of epithelioid or biphasic (predominantly [>50%] epithelioid) histology who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen.

STUDY DESIGN AND DURATION:

The study is an open-label, randomized, parallel group study conducted in patients with histologically confirmed MPM of epithelioid or biphasic (predominantly [>50%] epithelioid) histology who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen.

Screening assessments must be completed within 28 days of Study Day 1, and eligible patients will be randomized to either:

1. Treatment group: rAd-IFN (Study Day 1) + celecoxib (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 [i.e., Days 1 and 8 of the first gemcitabine treatment cycle], gemcitabine will be repeated every 3 weeks until disease progression/early termination [ET]); or

2. Control group: celecoxib (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 [i.e., Days 1 and 8 of the first gemcitabine treatment cycle], gemcitabine will be repeated every 3 weeks until disease progression/ET).

Treatment Phase Patients randomized to receive rAd-IFN (treatment group) will have an intrapleural catheter (IPC) or other intrapleural access device previously in place or inserted for the study, permitting drug administration to an accessible pleural space. The rAd-IFN will be diluted to a volume of 25 mL using sterile normal saline and will be administered directly to the pleural space via the IPC or similar device.

Patients will receive gemcitabine until disease progression/ET. All adverse events will be captured from the time of the main study's informed consent through 30 days after the last dose of study treatment (rAd-IFN, celecoxib, and/or gemcitabine). All treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) will be followed until resolution or stabilization.

Survival Follow-Up Phase Following disease progression, patients will be followed every 3 months for survival. All previously recorded TEAEs and SAEs will be followed until resolution or stabilization.

DOSAGE FORMS AND ROUTE OF ADMINISTRATION:

Patients randomized to the treatment group will receive rAd-IFN (3 × E11 viral particles) on Day 1 of the study, diluted to a total volume of 25 mL using sterile normal saline and administered into the pleural space via an IPC or similar intrapleural device.

All study patients (treatment and control) will receive:

- Celecoxib administered at a dose of 400 mg twice daily orally on Days 1 to 14 of the study; and

- Gemcitabine starting on Study Day 14, using the following treatment regimen: 1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day gemcitabine cycle and continued every 3 weeks until disease progression/ET.

STATISTICAL ANALYSES:

The primary analysis of the primary endpoint is a comparison of the OS curves between the 2 groups using a log-rank test. The log-rank test will be stratified using the same variables used for stratifying the randomization.

Secondary analyses of the primary endpoint will include a comparison of the survival rates at various time points since randomization and a comparison of the median survival times. The effect of baseline covariates will be assessed by constructing a proportional hazard model. Exploratory analyses will include comparison of the survival curves by methods that do not rely on proportional hazards.

Secondary time-to-event endpoints will be analyzed in the same manner as the primary efficacy endpoint.

Categorical efficacy endpoints will be summarized and compared between groups using a Pearson's test, with the effect of baseline covariates assessed using logistic regression.

The nature, incidence, severity, relatedness, expectedness, seriousness, and outcome of TEAEs will be summarized by treatment group for safety analyses.

There are 2 interim analyses planned:

- Analysis for futility will be assessed upon reaching 123 deaths (estimated to occur 27 months after first patient first visit [FPFV]). Approximately half of the available Beta will be spent at this interim; and

- Analysis for efficacy will be assessed upon reaching 234 deaths (estimated to occur 45 months after FPFV). Approximately one-fifth of the available Alpha will be spent at this interim.

The final analysis will be assessed upon reaching 267 deaths (estimated to occur 60 months after FPFV).

SAMPLE SIZE DETERMINATION:

The planned sample size is approximately 300 patients. Based on a 1:1 randomization between treatment groups, a 2.5% one-sided significance level, and a predicted survival at 18 months of 35% in the rAd-IFN treatment group versus 20% in the control group, the study will have at least 90% power (after adjusting for the interim analyses) to detect a statistically significant difference between the treatment groups in the primary endpoint using the log-rank test.

The calculation was based on the assumptions that recruitment is uniform over 3 years and that all alive patients are followed-up for 2 years after the end of recruitment.

DATA AND SAFETY MONITORING BOARD:

An independent Data and Safety Monitoring Board (DSMB) will be convened for this study to monitor safety, efficacy, and study integrity. All aspects of the DSMB's scope of review and procedures will be detailed in a DSMB charter.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.